Amylyx Pharmaceuticals (AMLX) Gains from Investment Securities (2021 - 2026)

Amylyx Pharmaceuticals' Gains from Investment Securities history runs 6 years deep, the most recent figure standing at $3.2 million for Q1 2026.

• In Q1 2026, Gains from Investment Securities rose 3061.0% year-over-year to $3.2 million; the TTM figure through Mar 2026 stood at $2.4 million (down 93.89% YoY), while the FY2025 annual figure was $9.4 million, up 21.73% from the prior year.
• Gains from Investment Securities was $3.2 million for Q1 2026 at Amylyx Pharmaceuticals, up from -$700000.0 in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $25.6 million in Q4 2023 to a low of -$700000.0 in Q4 2025.
• Historically, Gains from Investment Securities has averaged $5.2 million across 5 years, with a median of $2.4 million in 2025.
• The sharpest annual moves came in 2023 and 2025: Gains from Investment Securities jumped 16500.17% in 2023, then tumbled 434.35% in 2025.
• A 5-year view of Gains from Investment Securities shows it stood at $14.2 million in 2022, then surged by 79.78% to $25.6 million in 2023, then sank by 100.51% to -$131000.0 in 2024, then sank by 434.35% to -$700000.0 in 2025, then jumped by 551.57% to $3.2 million in 2026.
• The last three Gains from Investment Securities figures came in at $3.2 million (Q1 2026), -$700000.0 (Q4 2025), and $2.4 million (Q3 2025), per Business Quant data.